New data presented at the 2025 San Antonio Breast Cancer Symposium (SABCS) from the NRG/NSABP B-42 trial demonstrated that the Endocrine Activity Index (EAI) identifies postmenopausal women with ...

Norman Parathyroid Center, Clayman Thyroid Center, and Carling Adrenal Center Expand Their Lead as the World’s ...

About two thirds of breast cancers are classified as “hormone receptor positive” disease. These cancer cells express a group of proteins that bind to hormones, including estrogen and progesterone, ...

Researchers explored the link between medication adherence and symptom distress in patients with breast cancer undergoing endocrine therapy.

A novel artificial intelligence (AI) application capable of diagnosing endocrine cancers with speed and accuracy is being presented Sunday at ENDO 2025, the Endocrine Society's annual meeting in San ...

More than 40% of Americans with estrogen receptor (ER)-low early breast cancer did not receive endocrine therapy, analysis of a national database showed. Omitting endocrine therapy in ER-low breast ...

Verzenio plus endocrine therapy reduced death risk by 15.8% in high-risk early breast cancer patients compared to endocrine therapy alone. The monarchE trial showed improved OS and IDFS rates with ...

Median overall survival of 4 years with upfront CDK4/6 inhibition or in second line ...

Epigenome remodeling, including widespread changes to DNA methylation and 3D chromatin structure, is increasingly recognized as an important mechanism of gene deregulation in cancer. For example, at ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Most women with breast cancer who paused endocrine ...